KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Emergent BioSolutions (EBS) over the last 16 years, with Q3 2025 value amounting to $51.2 million.

  • Emergent BioSolutions' Net Income towards Common Stockholders fell 5540.07% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.9 million, marking a year-over-year increase of 13635.06%. This contributed to the annual value of -$190.6 million for FY2024, which is 7493.75% up from last year.
  • Emergent BioSolutions' Net Income towards Common Stockholders amounted to $51.2 million in Q3 2025, which was down 5540.07% from -$12.0 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Net Income towards Common Stockholders high stood at $177.9 million for Q4 2021, and its period low was -$283.1 million during Q2 2024.
  • Over the past 5 years, Emergent BioSolutions' median Net Income towards Common Stockholders value was -$31.3 million (recorded in 2024), while the average stood at -$44.1 million.
  • In the last 5 years, Emergent BioSolutions' Net Income towards Common Stockholders skyrocketed by 65760.0% in 2021 and then plummeted by 493243.24% in 2023.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Net Income towards Common Stockholders stood at $177.9 million in 2021, then tumbled by 137.66% to -$67.0 million in 2022, then rose by 26.12% to -$49.5 million in 2023, then soared by 36.77% to -$31.3 million in 2024, then skyrocketed by 263.58% to $51.2 million in 2025.
  • Its Net Income towards Common Stockholders stands at $51.2 million for Q3 2025, versus -$12.0 million for Q2 2025 and $68.0 million for Q1 2025.